The synthesis, biological evaluation and structure-activity relationship of 2-phenylaminomethylene-cyclohexane-1,3-diones as specific anti-tuberculosis agents.

Journal: MedChemComm
Published Date:

Abstract

The present study utilised whole cell based phenotypic screening of thousands of diverse small molecules against H37Rv () and identified the cyclohexane-1,3-dione-based structures and as hits. The selected hit molecules were used for further synthesis and a library of 37 compounds under four families was synthesized for lead generation. Evaluation of the library against lead to the identification of three lead antituberculosis agents (, and ). The most potential compound, 2-(((2-hydroxyphenyl)amino)methylene)-5,5-dimethylcyclohexane-1,3-dione () showed an MIC of 2.5 μg mL, which falls in the range of MICs values found for the known antituberculosis drugs ethambutol, streptomycin and levofloxacin. Additionally, this compound proved to be non-toxic (<20% inhibition at 50 μM concentration) against four human cell lines. Like first line antituberculosis drugs (isoniazid, rifampicin and pyrazinamide) this compound lacks activity against general Gram positive and Gram negative bacteria and even against ; thereby reflecting its highly specific antituberculosis activity.

Authors

  • Muzafar Ahmad Rather
    Clinical Microbiology and PK/PD Division, Clinical Microbiology PK/PD/Laboratory, CSIR-Indian Institute of Integrative Medicine, Sanatnagar, Srinagar, India-190005. Email: zahoorap@iiim.ac.in; ; Tel: +91 194 2431253/55; Tel: +91 9906593222.
  • Ali Mohd Lone
    Medicinal Chemistry Division, CSIR-Indian Institute of Integrative Medicine, Sanatnagar, Srinagar, India-190005. Email: khalidiiim@gmail.com; Email: bilal@iiim.ac.in; ; Tel: +91 1942431253/55.
  • Bisma Teli
    Medicinal Chemistry Division, CSIR-Indian Institute of Integrative Medicine, Sanatnagar, Srinagar, India-190005. Email: khalidiiim@gmail.com; Email: bilal@iiim.ac.in; ; Tel: +91 1942431253/55.
  • Zubair Shanib Bhat
    Clinical Microbiology and PK/PD Division, Clinical Microbiology PK/PD/Laboratory, CSIR-Indian Institute of Integrative Medicine, Sanatnagar, Srinagar, India-190005. Email: zahoorap@iiim.ac.in; ; Tel: +91 194 2431253/55; Tel: +91 9906593222.
  • Paramjeet Singh
    Cancer Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu, Jammu & Kashmir, India-180001.
  • Mubashir Maqbool
    Clinical Microbiology and PK/PD Division, Clinical Microbiology PK/PD/Laboratory, CSIR-Indian Institute of Integrative Medicine, Sanatnagar, Srinagar, India-190005. Email: zahoorap@iiim.ac.in; ; Tel: +91 194 2431253/55; Tel: +91 9906593222.
  • Bashir Ahmad Shairgojray
    Medicinal Chemistry Division, CSIR-Indian Institute of Integrative Medicine, Sanatnagar, Srinagar, India-190005. Email: khalidiiim@gmail.com; Email: bilal@iiim.ac.in; ; Tel: +91 1942431253/55.
  • Mohd Jamal Dar
    Academy of Scientific & Innovative Research (AcSIR), India.
  • Shajrul Amin
    Department of Biochemistry, University of Kashmir, Hazratbal Srinagar, India-190006.
  • Syed Khalid Yousuf
    Medicinal Chemistry Division, CSIR-Indian Institute of Integrative Medicine, Sanatnagar, Srinagar, India-190005. Email: khalidiiim@gmail.com; Email: bilal@iiim.ac.in; ; Tel: +91 1942431253/55.
  • Bilal A Bhat
    Medicinal Chemistry Division, CSIR-Indian Institute of Integrative Medicine, Sanatnagar, Srinagar, India-190005. Email: khalidiiim@gmail.com; Email: bilal@iiim.ac.in; ; Tel: +91 1942431253/55.
  • Zahoor Ahmad
    Clinical Microbiology and PK/PD Division, Clinical Microbiology PK/PD/Laboratory, CSIR-Indian Institute of Integrative Medicine, Sanatnagar, Srinagar, India-190005. Email: zahoorap@iiim.ac.in; ; Tel: +91 194 2431253/55; Tel: +91 9906593222.

Keywords

No keywords available for this article.